Overview

• The treatment targets energy production in affected eye cells, with studies indicating improvements in vision and quality of life.
• Eligibility covers people aged 12 and above with LHON, and evidence shows roughly half of treated patients see benefit.
• The medicine, branded Raxone by Chiesi, is taken as two tablets three times a day.
• The decision brings England into line with Wales and Scotland, where access had been available on a limited basis.
• LHON is a rare inherited disorder that can cause rapid, severe vision loss and affects an estimated 2,000 people in England.